Aura Biosciences Inc
AURA
Company Profile
Business description
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Contact
80 Guest Street
BostonMA02135
USAT: +1 617 500-8864
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
106
Stocks News & Analysis
stocks
Finding yield on the ASX
The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
We’ve raised our fair value estimate of Exxon stock.
stocks
Disney earnings: No big surprises in solid results
Growth in areas critical to the firm’s future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 6.90 | -0.08% |
| CAC 40 | 8,180.69 | 0.48 | -0.01% |
| DAX 40 | 24,840.03 | 42.51 | 0.17% |
| Dow JONES (US) | 49,407.66 | 515.19 | 1.05% |
| FTSE 100 | 10,296.88 | 44.68 | -0.43% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,592.11 | 130.29 | 0.56% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,976.44 | 37.41 | 0.54% |
| S&P/ASX 200 | 8,857.10 | 9.20 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |